A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

William J. Gradishar(Northwestern University), Virginia Kaklamani(Northwestern University), Tarini Prasad Sahoo(Jawaharlal Nehru Cancer Hospital and Research Centre), D. Lokanatha(Kidwai Memorial Institute of Oncology), Vinod Raina(All India Institute of Medical Sciences), Shailesh Bondarde, Minish Jain(Ruby Hall Clinic), Sunhee Ro, Nathalie A. Lokker, Lee S. Schwartzberg
European Journal of Cancer
September 3, 2012
Cited by 85

Abstract


Related Papers

No related papers found

Powered by citation graph analysis